[go: up one dir, main page]

MX2015002170A - Novel pharmaceutical compositions useful for treating hypertension. - Google Patents

Novel pharmaceutical compositions useful for treating hypertension.

Info

Publication number
MX2015002170A
MX2015002170A MX2015002170A MX2015002170A MX2015002170A MX 2015002170 A MX2015002170 A MX 2015002170A MX 2015002170 A MX2015002170 A MX 2015002170A MX 2015002170 A MX2015002170 A MX 2015002170A MX 2015002170 A MX2015002170 A MX 2015002170A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
novel pharmaceutical
eprosartan
active ingredients
lercanidipine
Prior art date
Application number
MX2015002170A
Other languages
Spanish (es)
Inventor
Manuel Francisco Lara Ochoa Jose
Original Assignee
Invekra S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invekra S A P I De C V filed Critical Invekra S A P I De C V
Priority to MX2015002170A priority Critical patent/MX2015002170A/en
Priority to PCT/IB2015/059752 priority patent/WO2016132193A1/en
Priority to ARP160100395A priority patent/AR103679A1/en
Priority to UY0001036556A priority patent/UY36556A/en
Publication of MX2015002170A publication Critical patent/MX2015002170A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to novel pharmaceutical compositions for treating patients with hypertension, which use, as active ingredients, the second-generation angiotensin II receptor type 1 blocker eprosartan combined with the third-generation calcium antagonist lercanidipine and the diuretic hydrochlorothiazide. These active ingredients, eprosartan, lercanidipine and hydrochlorothiazide, have proven, as single agents, to be more effective and to have less adverse effects and an increased tolerance compared to other, commercially available, hypertensives. The combinations are produced in the form of immediate-release and sustained-release tablets, as well as powders for a suspension, the latter composition being useful for certain states of patients whose physical state does not allow the ingestion of tablets or capsules and an intravenous injectable form has been developed for cases where immediate bioavailability is required.
MX2015002170A 2015-02-18 2015-02-18 Novel pharmaceutical compositions useful for treating hypertension. MX2015002170A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2015002170A MX2015002170A (en) 2015-02-18 2015-02-18 Novel pharmaceutical compositions useful for treating hypertension.
PCT/IB2015/059752 WO2016132193A1 (en) 2015-02-18 2015-12-17 Pharmaceutical composition comprising hydrochlorothiazide, eprosartan and lercanidipine, useful for treating hypertension
ARP160100395A AR103679A1 (en) 2015-02-18 2016-02-12 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
UY0001036556A UY36556A (en) 2015-02-18 2016-02-16 NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015002170A MX2015002170A (en) 2015-02-18 2015-02-18 Novel pharmaceutical compositions useful for treating hypertension.

Publications (1)

Publication Number Publication Date
MX2015002170A true MX2015002170A (en) 2016-08-17

Family

ID=56692112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002170A MX2015002170A (en) 2015-02-18 2015-02-18 Novel pharmaceutical compositions useful for treating hypertension.

Country Status (4)

Country Link
AR (1) AR103679A1 (en)
MX (1) MX2015002170A (en)
UY (1) UY36556A (en)
WO (1) WO2016132193A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043395A1 (en) * 2003-02-28 2005-07-27 Recordati Ireland Ltd COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS

Also Published As

Publication number Publication date
AR103679A1 (en) 2017-05-24
WO2016132193A1 (en) 2016-08-25
UY36556A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
CY1118183T1 (en) PHARMACEUTICAL FORM THAT CONTAINS NIFEDIPIN OR NISOLDIPIN AND AN ANGIOTENSIN II COMPONENT / AND A DIRECTIVE
MX371432B (en) Tamper-resistant dosage form containing one or more particles.
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MX395710B (en) MULTICOMPONENT GUMMY COMPOSITIONS WITH A HARD CORE.
CY1115652T1 (en) DOSAGE FORM THAT CONTAINS TWO ACTIVE MEDICINAL MIXING INGREDIENTS IN DIFFERENT NATURAL FORMS
JP2016147915A5 (en)
PH12014501813A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
JP2018527305A5 (en)
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
MX385820B (en) ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
MX2018000084A (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin.
RU2014129508A (en) NEW COMBINATION
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
UA115257C2 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
EA201991490A1 (en) AROMATIC AMIDES OF CARBOXYLIC ACIDS AS BRAKININ B1 RECEPTOR ANTAGONISTS
PE20130004A1 (en) SOLID PHARMACEUTICAL FORMULATIONS OF RAMIPRIL AND AMLODIPINE BESYLATE AND THEIR PREPARATION
MX2021014830A (en) CONJUGATES OF <i>π</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS.
EA201170583A1 (en) NEW COMPOSITION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTEMIA
MX2015002170A (en) Novel pharmaceutical compositions useful for treating hypertension.
MX2015002169A (en) Pharmaceutical compositions for treating hypertension, based on a novel drug combination.
EA201390844A1 (en) COMPLEX COMPOSITION CONTAINING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR ITS PREPARATION
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
MX2015015681A (en) Pharmaceutical composition comprising fingolimod.
MX2023000479A (en) Swellable oral pharmaceutical compositions.